Insider Selling: Twist Bioscience (NASDAQ:TWST) CEO Sells $919,378.20 in Stock

Posted by Brian Himes on Oct 10th, 2026

Twist Bioscience Corporation (NASDAQ:TWST – Get Free Report) CEO Emily Leproust sold 4,548 shares of the firm’s stock in a transaction dated Monday, October 5th. The shares were sold at an average price of $202.15, for a total value of $919,378.20. Following the transaction, the chief executive officer directly owned 562,760 shares in the company, valued at approximately $113,761,934. This represents a 0.80% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Twist Bioscience Stock Up 5.1%

Shares of TWST opened at $159.78 on Friday. The firm has a market cap of $10.02 billion, a P/E ratio of -71.97 and a beta of 2.19. The stock has a 50 day simple moving average of $144.32 and a two-hundred day simple moving average of $96.40. The company has a debt-to-equity ratio of 0.03, a current ratio of 2.67 and a quick ratio of 2.38. Twist Bioscience Corporation has a 1 year low of $23.30 and a 1 year high of $219.71.

Twist Bioscience (NASDAQ:TWST – Get Free Report) last posted its quarterly earnings results on Monday, August 3rd. The company reported ($0.56) EPS for the quarter, missing the consensus estimate of ($0.51) by ($0.05). The business had revenue of $118.38 million for the quarter, compared to analysts’ expectations of $114.55 million. Twist Bioscience had a negative return on equity of 28.64% and a negative net margin of 31.66%. The company’s revenue was up 23.2% compared to the same quarter last year. During the same period last year, the business posted $0.33 earnings per share. On average, analysts forecast that Twist Bioscience Corporation will post -2.12 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Twist Bioscience

Several hedge funds have recently made changes to their positions in the company. BlackRock Inc. purchased a new position in Twist Bioscience during the second quarter valued at $600,191,000. William Blair Investment Management LLC bought a new position in shares of Twist Bioscience in the 2nd quarter worth about $223,722,000. Bank of America Corp DE bought a new position in shares of Twist Bioscience in the 2nd quarter worth about $94,922,000. Allspring Global Investments Holdings LLC purchased a new position in Twist Bioscience during the 1st quarter valued at about $22,563,000. Finally, Bank of New York Mellon Corp purchased a new position in Twist Bioscience during the 2nd quarter valued at about $19,722,000.

Analyst Upgrades and Downgrades

Several research firms have issued reports on TWST. Evercore lowered shares of Twist Bioscience from an “outperform” rating to an “in-line” rating and set a $102.00 price target for the company. in a research report on Monday, July 6th. Barclays raised their target price on shares of Twist Bioscience from $112.00 to $215.00 and gave the stock an “overweight” rating in a report on Wednesday. BWS Financial reiterated a “sell” rating and set a $45.00 price target on shares of Twist Bioscience in a report on Friday, September 18th. Guggenheim increased their price target on shares of Twist Bioscience from $107.00 to $212.00 and gave the company a “buy” rating in a research report on Thursday, October 1st. Finally, TD Cowen reissued a “buy” rating on shares of Twist Bioscience in a report on Monday, August 3rd. Eight research analysts have rated the stock with a Buy rating, three have given a Hold rating and two have given a Sell rating to the stock. According to data from MarketBeat, the company has a consensus rating of “Hold” and a consensus price target of $128.17.

Get Our Latest Research Report on TWST

Twist Bioscience Company Profile

(Get Free Report)

Twist Bioscience Corporation (NASDAQ:TWST) is a biotechnology company that develops and manufactures synthetic DNA using a silicon-based production platform. Its technology is designed to enable the precise, high-throughput synthesis of DNA at smaller scale and with potentially lower material consumption than traditional methods.

The company provides synthetic DNA products and services for applications in drug discovery and development, biotechnology research, agriculture, industrial chemicals and other life sciences markets.